EE03526B1 - Leukotrieen-antagonistliku toimega bensopüraanderivaadid, nende valmistamismeetod ja kasutamine - Google Patents

Leukotrieen-antagonistliku toimega bensopüraanderivaadid, nende valmistamismeetod ja kasutamine

Info

Publication number
EE03526B1
EE03526B1 EE9800318A EE9800318A EE03526B1 EE 03526 B1 EE03526 B1 EE 03526B1 EE 9800318 A EE9800318 A EE 9800318A EE 9800318 A EE9800318 A EE 9800318A EE 03526 B1 EE03526 B1 EE 03526B1
Authority
EE
Estonia
Prior art keywords
pct
compounds
preparation
antagonist activity
leukotriene antagonist
Prior art date
Application number
EE9800318A
Other languages
English (en)
Estonian (et)
Other versions
EE9800318A (et
Inventor
Carganico Germano
Mauleon Casellas David
Pascual Avellana Jaime
Garcia Perez Luisa
Palomer Benet Albert
Original Assignee
Laboratorios Menarini S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Menarini S.A. filed Critical Laboratorios Menarini S.A.
Publication of EE9800318A publication Critical patent/EE9800318A/xx
Publication of EE03526B1 publication Critical patent/EE03526B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/51—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition
    • C07C45/54—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition of compounds containing doubly bound oxygen atoms, e.g. esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
EE9800318A 1996-03-21 1997-03-20 Leukotrieen-antagonistliku toimega bensopüraanderivaadid, nende valmistamismeetod ja kasutamine EE03526B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES009600682A ES2127106B1 (es) 1996-03-21 1996-03-21 Derivados benzopiranicos con accion antagonista de los leucotrienos, procedimiento para su preparacion y utilizacion de los mismos.
PCT/EP1997/001418 WO1997034885A1 (en) 1996-03-21 1997-03-20 Benzopyran derivatives having leukotriene-antagonistic action

Publications (2)

Publication Number Publication Date
EE9800318A EE9800318A (et) 1999-04-15
EE03526B1 true EE03526B1 (et) 2001-10-15

Family

ID=8294261

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800318A EE03526B1 (et) 1996-03-21 1997-03-20 Leukotrieen-antagonistliku toimega bensopüraanderivaadid, nende valmistamismeetod ja kasutamine

Country Status (30)

Country Link
US (1) US5990142A (cs)
EP (1) EP0888327B1 (cs)
JP (1) JP3914575B2 (cs)
KR (1) KR100378892B1 (cs)
CN (1) CN1182129C (cs)
AT (1) ATE219073T1 (cs)
AU (1) AU707282B2 (cs)
BG (1) BG63433B1 (cs)
BR (1) BR9708215A (cs)
CA (1) CA2249402C (cs)
CU (1) CU22777A3 (cs)
CZ (1) CZ296260B6 (cs)
DE (1) DE69713300T2 (cs)
DK (1) DK0888327T3 (cs)
EA (1) EA001680B1 (cs)
EE (1) EE03526B1 (cs)
ES (2) ES2127106B1 (cs)
GE (1) GEP20012416B (cs)
HU (1) HUP9901326A3 (cs)
IL (1) IL126296A (cs)
NO (1) NO319612B1 (cs)
NZ (1) NZ331953A (cs)
PL (1) PL189562B1 (cs)
PT (1) PT888327E (cs)
RS (1) RS49588B (cs)
SI (1) SI0888327T1 (cs)
SK (1) SK282979B6 (cs)
TR (1) TR199801857T2 (cs)
UA (1) UA65535C2 (cs)
WO (1) WO1997034885A1 (cs)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001038582A1 (en) 1999-11-24 2001-05-31 The Research Foundation Of State University Of New York CATALYTIC RNAs WITH AMINOACYLATION ACTIVITY
AU2003213136A1 (en) * 2002-02-15 2003-09-09 The Research Foundation Of State University Of New York At Buffalo RIBOZYMES WITH BROAD tRNA AMINOACYLATION ACTIVITY
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
AU2003301305A1 (en) * 2002-10-17 2004-05-04 Decode Genetics Ehf. Susceptibility gene for myocardial infarction; methods of treatment
ITTO20030140U1 (it) * 2003-09-16 2005-03-17 Interfila Srl Matita cosmetica
WO2005032544A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Treatment of mitochondrial diseases
CN100475781C (zh) * 2004-02-13 2009-04-08 沃尼尔·朗伯有限责任公司 雄激素受体调节剂
EA009902B1 (ru) * 2004-02-13 2008-04-28 УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си Модуляторы рецепторов андрогенов
US7507860B2 (en) 2004-04-13 2009-03-24 Pfizer Inc. Androgen modulators
EP1781598A1 (en) * 2004-07-08 2007-05-09 Warner-Lambert Company LLC Androgen modulators
BRPI0514469A (pt) * 2004-08-18 2008-06-10 Warner Lambert Co moduladores de androgênio
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
US20090170886A1 (en) * 2005-08-08 2009-07-02 Pfizer Inc Androgen modulators
US8188260B2 (en) * 2005-12-06 2012-05-29 The University Of Tokyo Versatile acylation catalytic RNAs and uses thereof
ITMI20061606A1 (it) * 2006-08-09 2008-02-10 Dipharma Spa Procedimento per la preparazione di composti nitrilici
CN102304052A (zh) * 2011-07-28 2012-01-04 浙江大学 一种制备5-溴-2-羟基-3-硝基苯乙酮的方法
CN103980257B (zh) * 2014-05-28 2016-04-27 苏州开元民生科技股份有限公司 8-硝基-2-四氮唑基-4-羰基苯并吡喃的合成方法
CN104402711A (zh) * 2014-11-12 2015-03-11 平湖优康药物研发有限公司 一种抗哮喘药物普伦斯特中间体的合成工艺
CN113651788B (zh) * 2021-09-16 2023-11-21 东华理工大学 一种3-胺烷基色酮化合物及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4977162A (en) * 1989-07-13 1990-12-11 Rorer Pharmaceutical Corporation Quinolinyl-chromone derivatives and use for treatment of hypersensitive ailments
JPH0395144A (ja) * 1989-08-04 1991-04-19 Ono Pharmaceut Co Ltd アミノフェノール誘導体の製造方法

Also Published As

Publication number Publication date
CA2249402A1 (en) 1997-09-25
JP2000506878A (ja) 2000-06-06
YU40798A (en) 1999-11-22
CA2249402C (en) 2006-10-24
EP0888327B1 (en) 2002-06-12
KR100378892B1 (ko) 2005-11-14
ES2176719T3 (es) 2002-12-01
AU707282B2 (en) 1999-07-08
BG63433B1 (bg) 2002-01-31
WO1997034885A1 (en) 1997-09-25
PL189562B1 (pl) 2005-08-31
HUP9901326A2 (hu) 1999-08-30
IL126296A (en) 2002-08-14
IL126296A0 (en) 1999-05-09
HK1018701A1 (en) 1999-12-30
NO984330L (no) 1998-10-09
JP3914575B2 (ja) 2007-05-16
SK127298A3 (en) 1999-03-12
PL329027A1 (en) 1999-03-01
GEP20012416B (en) 2001-04-25
PT888327E (pt) 2002-11-29
SI0888327T1 (en) 2002-10-31
ATE219073T1 (de) 2002-06-15
CZ299598A3 (cs) 1999-03-17
CN1214048A (zh) 1999-04-14
CU22777A3 (es) 2002-07-24
DE69713300D1 (de) 2002-07-18
EA199800738A1 (ru) 1999-06-24
EE9800318A (et) 1999-04-15
CN1182129C (zh) 2004-12-29
RS49588B (sr) 2007-06-04
HUP9901326A3 (en) 2000-12-28
EP0888327A1 (en) 1999-01-07
BG102775A (en) 1999-08-31
NO319612B1 (no) 2005-08-29
DK0888327T3 (da) 2002-09-16
SK282979B6 (sk) 2003-01-09
AU2158797A (en) 1997-10-10
DE69713300T2 (de) 2002-09-26
UA65535C2 (en) 2004-04-15
KR20000064682A (ko) 2000-11-06
TR199801857T2 (xx) 1998-12-21
NZ331953A (en) 1999-03-29
ES2127106B1 (es) 1999-11-16
US5990142A (en) 1999-11-23
CZ296260B6 (cs) 2006-02-15
NO984330D0 (no) 1998-09-17
BR9708215A (pt) 2000-01-04
ES2127106A1 (es) 1999-04-01
EA001680B1 (ru) 2001-06-25

Similar Documents

Publication Publication Date Title
EE03526B1 (et) Leukotrieen-antagonistliku toimega bensopüraanderivaadid, nende valmistamismeetod ja kasutamine
FI934983A0 (fi) Kinuklidinderivat foer behandling av inflammatoriska och gastrointestinala sjukdomar
EE200100010A (et) Kinoliini derivaadid, nende kasutamine ravimina, neid sisaldavad farmatseutilised kompositsioonid ning ühendite ja farmatseutiliste kompositsioonide kasutamine patoloogilisest põletikust ja autoimmuunsusest tingitud haiguste ravis
ATE175114T1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin- vermittelten krankheiten
DK0687268T3 (da) Spiroazacykliske derivater som substans P-antagonister
PT641328E (pt) Derivados aza-biciclicos em ponte como antagonistas da substancia p
SE9604786D0 (sv) New compounds
BR9811482A (pt) Derivados de 1-(n-fenilaminoalquil)-piperazina substituìda na posição 2 do anel fenìlico
NO20093464L (no) Nye medikamentblandinger basert pa anti-cholinergisk effektive forbindelser og beta-mimetika
ES2169362T3 (es) Glicoconjugados de derivados modificados de la camptotecina (union al ciclo a o b).
MXPA04003874A (es) 6-hidroxi isoflavonas, derivados y medicamentos que las contienen.
DE59706808D1 (de) Verwendung von 7-(2-oxa-5,8-diazabicyclo 4.3.0]non-8-yl)-chinoloncarbonsäure- und -naphthyridoncarbonsäure-derivaten zur herstellung eines arzneimittels zur therapie von helicobacter-pylori-infektionen und den damit assoziierten gastroduodenalen erkrankungen
EE200100007A (et) Kinoliini derivaadid, nende kasutamine ravimina, neid sisaldavad farmatseutilised kompositsioonid ning ühendite ja farmatseutiliste kompositsioonide kasutamine patoloogilisest põletikust ja autoimmuunsusest tingitud haiguste ravis
ATE234282T1 (de) Polymorphe verbindungen
UA34416C2 (uk) Похідні хроману, активні стосовно 5-нт рецептора, спосіб їх одержання та проміжні сполуки
ATE218350T1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
EE04039B1 (et) Farmatseutiline kompositsioon peroraalseks manustamiseks, selle valmistamismeetod ja kasutamine
TR199900486T2 (xx) Aziniloksi ve fenoksi-diaril-karbonasit t�revleri.
RU95111308A (ru) Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция
MX9300779A (es) 3-(1h-tetrazol-5-y1)-4h-pyrido[1,2-a]pirimidina-4-onas composiciones farmaceuticas que las contienen y su preparacion de las mismas
BR9503572A (pt) Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença
AU4080097A (en) Piperazino derivatives as neurokinin antagonists
UY26426A1 (es) Nuevos compuestos
BG102707A (bg) Нови триазолопурини, метод за тяхното получаване и тяхното приложение като лекарствени средства
HUP0103712A2 (hu) Paroxetin sók, eljárás az előállításukra és gyógyászati alkalmazásuk

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

MM4A Lapsed by not paying the annual fees

Effective date: 20100320